SignalChem

Stratech

stratech.co.uk/signalchem
info@stratech.co.uk

Anti-2019-nCoV Spike Protein Neutralizing Nanobody (NBX20038)

Catalog No: C19S1-652L

The SARS-CoV-2 receptor-binding domain (RBD) of the spike protein facilitates the binding of the virus to the human angiotensin-converting enzyme 2(hACE2) for cellular entry. As the virus mutates, it creates variants presenting key mutations on its Spike protein evading the host neutralizing antibodies. Single domain heavy chain antibodies generated in llama have shown to recognize these new variants and block the binding of SARS-CoV-2/ ACE2 through neutralization. SignalChem's recombinant llama-VHH have been engineered to study neutralization of SARS-CoV-2 and detect the 2019 -nCoV Spike Protein.

Unique Selling Points

- Neutralizing activity validated for wild type RBD
- Recognizes SARS-CoV-2 S protein
- Biologically active
- Neutralizing activity validated for N501Y variant



Competitors

AssayGenie

abbexa®

CUSABIO®

Target Customers

- Biopharma developing Anti-SARS-CoV-2 therapies
- University researchers studying SARS-CoV-2 neutralization
- Scientists developing diagnostic tests
- Biotech companies developing vaccines
- Government research organizations

www.signalchem.com
1.866.954.6273
info@signalchem.com

Anti 2019-nCoV Spike Protein Neutralizing Nanobody (NBX20038)

Catalog No: C19S1-642HL

The spike glycoprotein (S) of coronavirus is a type I transmembrane protein containing two subunits, S1 and S2, and is a key component in binding with the hACE2. As the virus mutates, the new variants evade host's neutralizing antibody response, making the new variants more potent. Recombinant nanobodies derived from camelids can target unique epitopes even on the RBDs of new variants, which are harder to be accessed by regular mAbs. SignalChem's recombinant llama VHH-Human IgG Antibody have been generated in llama for studying neutralization of SARS-CoV-2 and detection of 2019-nCoV Spike Protein.

Applications

- COVID19 ELISAs
- Nanobody based Therapies R&D
- COVID19 Protein Arrays
- Diagnostic kits R&D
- Vaccine Research



Assay Data



Binding ability measured in a functional ELISA. Anti 2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-642HL) binds 2019-nCoV Spike protein RBD.



Inhibitory activity of Anti 2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-642HL) against 2019-nCoV RBD binding to ACE2(19-740) protein determined using ELISA.